Review article · 2024 · Open access

Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance

Kampanart Huanbutta, Kanokporn Burapapadh, Pakorn Kraisit, Pornsak Sriamornsak, Thittaporn Ganokratanaa, Kittipat Suwanpitak, Tanikan Sangnim

European Journal of Pharmaceutical Sciences, 203, 106938 · Published 16 October 2024 · DOI 10.1016/j.ejps.2024.106938

Read the free full textCite this paper

In brief

“Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance” is a 2024 review article by Kampanart Huanbutta and 6 co-authors, published in European Journal of Pharmaceutical Sciences. OpenAlex counts 194 citations as of 15 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at European Journal of Pharmaceutical Sciences.

Citations
194
Most cited in
2026 (104)
Field-weighted impact
4.97
References
162
Authors
7

Abstract

The advent of artificial intelligence (AI) has catalyzed a profound transformation in the pharmaceutical industry, ushering in a paradigm shift across various domains, including drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. This comprehensive review examines the multifaceted impact of AI-driven technologies on all stages of the pharmaceutical life cycle. It discusses the application of machine learning algorithms, data analytics, and predictive modeling to accelerate drug discovery processes, optimize formulation development, enhance manufacturing efficiency, ensure stringent quality control measures, and revolutionize post-market surveillance methodologies. By describing the advancements, challenges, and future prospects of harnessing AI in the pharmaceutical landscape, this review offers valuable insights into the evolving dynamics of drug development and regulatory practices in the era of AI-driven innovation.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Huanbutta, K., Burapapadh, K., Kraisit, P., Sriamornsak, P., Ganokratanaa, T., Suwanpitak, K., & Sangnim, T. (2024). Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. European Journal of Pharmaceutical Sciences, 203, 106938. https://doi.org/10.1016/j.ejps.2024.106938

MLA 9

Huanbutta, Kampanart, et al. “Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance.” European Journal of Pharmaceutical Sciences, vol. 203, 2024, p. 106938. https://doi.org/10.1016/j.ejps.2024.106938.

Chicago

Huanbutta, Kampanart, Kanokporn Burapapadh, Pakorn Kraisit, Pornsak Sriamornsak, Thittaporn Ganokratanaa, Kittipat Suwanpitak, and Tanikan Sangnim. 2024. “Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance.” European Journal of Pharmaceutical Sciences 203: 106938. https://doi.org/10.1016/j.ejps.2024.106938.

Harvard

Huanbutta, K. et al. (2024) ‘Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance’, European Journal of Pharmaceutical Sciences, 203, p. 106938. doi:10.1016/j.ejps.2024.106938.

IEEE

K. Huanbutta et al., “Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance,” European Journal of Pharmaceutical Sciences, vol. 203, p. 106938, 2024, doi: 10.1016/j.ejps.2024.106938.

BibTeX

@article{huanbutta2024artificial,
  title     = {{Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance}},
  author    = {Huanbutta, Kampanart and Burapapadh, Kanokporn and Kraisit, Pakorn and Sriamornsak, Pornsak and Ganokratanaa, Thittaporn and Suwanpitak, Kittipat and Sangnim, Tanikan},
  journal   = {European Journal of Pharmaceutical Sciences},
  year      = {2024},
  volume    = {203},
  pages     = {106938},
  doi       = {10.1016/j.ejps.2024.106938},
  url       = {https://doi.org/10.1016/j.ejps.2024.106938}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201511
202466
20258383
2026104104

Its field-weighted citation impact is 4.97: it has been cited 4.97 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • artificial intelligence in pharmaceuticals
  • drug discovery
  • drug formulation development
  • pharmaceutical manufacturing
  • quality control
  • post-marketing surveillance
  • machine learning
  • predictive modeling

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Huanbutta, K., Burapapadh, K., Kraisit, P., Sriamornsak, P., Ganokratanaa, T., Suwanpitak, K., & Sangnim, T. (2024). Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. European Journal of Pharmaceutical Sciences, 203, 106938. https://doi.org/10.1016/j.ejps.2024.106938

How many times has this paper been cited?

194 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at European Journal of Pharmaceutical Sciences.

Who wrote this paper?

Kampanart Huanbutta, Kanokporn Burapapadh, Pakorn Kraisit, Pornsak Sriamornsak, Thittaporn Ganokratanaa, Kittipat Suwanpitak, Tanikan Sangnim.

What is the DOI of this paper?

10.1016/j.ejps.2024.106938. The permanent link is https://doi.org/10.1016/j.ejps.2024.106938.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.